Teyi Pharmaceutical Group Co Ltd (SHE:002728) — Market Cap & Net Worth
Market Cap & Net Worth: Teyi Pharmaceutical Group Co Ltd (002728)
Teyi Pharmaceutical Group Co Ltd (SHE:002728) has a market capitalization of $724.09 Million (CN¥4.95 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10480 globally and #2837 in its home market, demonstrating a 4.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Teyi Pharmaceutical Group Co Ltd's stock price CN¥9.64 by its total outstanding shares 513309812 (513.31 Million). Also see 002728 total assets for a full breakdown of the balance sheet.
Teyi Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Teyi Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $745.90 Million to $724.09 Million (2.11% CAGR). Also see cash flow conversion of Teyi Pharmaceutical Group Co Ltd for how efficiently the company converts equity into cash flow.
Teyi Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Teyi Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Teyi Pharmaceutical Group Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.89x
Teyi Pharmaceutical Group Co Ltd's market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.98x
Teyi Pharmaceutical Group Co Ltd's market cap is 9.98 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $692.91 Million | $655.86 Million | $94.78 Million | 1.06x | 7.31x |
| 2017 | $469.38 Million | $686.94 Million | $106.34 Million | 0.68x | 4.41x |
| 2018 | $354.25 Million | $884.98 Million | $155.55 Million | 0.40x | 2.28x |
| 2019 | $487.57 Million | $921.12 Million | $171.71 Million | 0.53x | 2.84x |
| 2020 | $363.71 Million | $632.70 Million | $43.82 Million | 0.57x | 8.30x |
| 2021 | $553.05 Million | $758.16 Million | $126.92 Million | 0.73x | 4.36x |
| 2022 | $781.12 Million | $886.57 Million | $178.20 Million | 0.88x | 4.38x |
| 2023 | $913.99 Million | $1.07 Billion | $253.18 Million | 0.86x | 3.61x |
| 2024 | $672.26 Million | $687.79 Million | $20.50 Million | 0.98x | 32.80x |
| 2025 | $814.98 Million | $915.67 Million | $81.67 Million | 0.89x | 9.98x |
Competitor Companies of 002728 by Market Capitalization
Companies near Teyi Pharmaceutical Group Co Ltd in the global market cap rankings as of September 19, 2026. Review Teyi Pharmaceutical Group Co Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Teyi Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Teyi Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Teyi Pharmaceutical Group Co Ltd's market cap moved from $745.90 Million to $ 724.09 Million, with a yearly change of 2.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥724.09 Million | -11.15% |
| 2025 | CN¥814.98 Million | +21.23% |
| 2024 | CN¥672.26 Million | -26.45% |
| 2023 | CN¥913.99 Million | +17.01% |
| 2022 | CN¥781.12 Million | +41.24% |
| 2021 | CN¥553.05 Million | +52.06% |
| 2020 | CN¥363.71 Million | -25.40% |
| 2019 | CN¥487.57 Million | +37.63% |
| 2018 | CN¥354.25 Million | -24.53% |
| 2017 | CN¥469.38 Million | -32.26% |
| 2016 | CN¥692.91 Million | -7.10% |
| 2015 | CN¥745.90 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Teyi Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $724.09 Million USD |
| MoneyControl | $724.09 Million USD |
| MarketWatch | $724.09 Million USD |
| marketcap.company | $724.09 Million USD |
| Reuters | $724.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Gua… Read more